home / stock / phge / phge quote
Last: | $0.35 |
---|---|
Change Percent: | 4.17% |
Open: | $0.322 |
Close: | $0.35 |
High: | $0.35 |
Low: | $0.32 |
Volume: | 160,201 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.35 | $0.322 | $0.35 | $0.35 | $0.32 | 160,201 | 04-26-2024 |
$0.336 | $0.325 | $0.336 | $0.344 | $0.3065 | 92,885 | 04-25-2024 |
$0.3399 | $0.3465 | $0.3399 | $0.35 | $0.315 | 126,326 | 04-24-2024 |
$0.3465 | $0.33 | $0.3465 | $0.35 | $0.300201 | 221,045 | 04-23-2024 |
$0.2951 | $0.31 | $0.2951 | $0.34 | $0.29 | 194,966 | 04-22-2024 |
$0.29 | $0.282 | $0.29 | $0.2981 | $0.2802 | 69,439 | 04-19-2024 |
$0.2958 | $0.2799 | $0.2958 | $0.31 | $0.2787 | 118,347 | 04-18-2024 |
$0.2801 | $0.2803 | $0.2801 | $0.320001 | $0.2725 | 130,804 | 04-17-2024 |
$0.2803 | $0.3 | $0.2803 | $0.3018 | $0.2675 | 187,748 | 04-16-2024 |
$0.3001 | $0.319 | $0.3001 | $0.3307 | $0.3 | 160,459 | 04-15-2024 |
$0.315 | $0.35 | $0.315 | $0.35 | $0.31 | 72,654 | 04-12-2024 |
$0.3253 | $0.339 | $0.3253 | $0.3399 | $0.3105 | 133,099 | 04-11-2024 |
$0.3415 | $0.36 | $0.3415 | $0.36 | $0.3415 | 147,878 | 04-10-2024 |
$0.351 | $0.36 | $0.351 | $0.369 | $0.345 | 118,059 | 04-09-2024 |
$0.3579 | $0.3632 | $0.3579 | $0.3973 | $0.3577 | 188,594 | 04-08-2024 |
$0.3797 | $0.39 | $0.3797 | $0.4 | $0.365 | 303,799 | 04-05-2024 |
$0.38 | $0.39 | $0.38 | $0.39 | $0.36 | 393,595 | 04-04-2024 |
$0.35 | $0.41 | $0.35 | $0.42 | $0.35 | 411,067 | 04-03-2024 |
$0.3842 | $0.3997 | $0.3842 | $0.44 | $0.37 | 653,526 | 04-02-2024 |
$0.4095 | $0.4307 | $0.4095 | $0.44 | $0.381 | 452,359 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Chardan Healthcare Acquisition Corp. Company Name:
PHGE Stock Symbol:
NYSE Market:
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today anno...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today anno...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that, as previously discl...